NO20024381L - Preparat for anvendelse ved behandling av okular hypertensjon og gluakom - Google Patents

Preparat for anvendelse ved behandling av okular hypertensjon og gluakom

Info

Publication number
NO20024381L
NO20024381L NO20024381A NO20024381A NO20024381L NO 20024381 L NO20024381 L NO 20024381L NO 20024381 A NO20024381 A NO 20024381A NO 20024381 A NO20024381 A NO 20024381A NO 20024381 L NO20024381 L NO 20024381L
Authority
NO
Norway
Prior art keywords
treatment
glaucoma
preparation
ocular hypertension
prostaglandin
Prior art date
Application number
NO20024381A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024381D0 (no
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/730,830 external-priority patent/US20010034355A1/en
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of NO20024381D0 publication Critical patent/NO20024381D0/no
Publication of NO20024381L publication Critical patent/NO20024381L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20024381A 2000-03-16 2002-09-13 Preparat for anvendelse ved behandling av okular hypertensjon og gluakom NO20024381L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52757300A 2000-03-16 2000-03-16
US09/730,830 US20010034355A1 (en) 2000-03-16 2000-12-07 Treatment of ocular hypertension
PCT/JP2001/002035 WO2001068072A2 (en) 2000-03-16 2001-03-15 Composition for use in treatment of ocular hypertension and glaucoma

Publications (2)

Publication Number Publication Date
NO20024381D0 NO20024381D0 (no) 2002-09-13
NO20024381L true NO20024381L (no) 2002-11-15

Family

ID=27062443

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024381A NO20024381L (no) 2000-03-16 2002-09-13 Preparat for anvendelse ved behandling av okular hypertensjon og gluakom

Country Status (18)

Country Link
US (1) US20010056104A1 (https=)
EP (1) EP1272194A2 (https=)
JP (1) JP2003526660A (https=)
KR (1) KR20080012407A (https=)
CN (1) CN100506232C (https=)
AR (1) AR029818A1 (https=)
AU (2) AU2001241143B2 (https=)
BR (1) BR0109192A (https=)
CA (1) CA2402597C (https=)
CZ (1) CZ20023092A3 (https=)
HU (1) HUP0300391A3 (https=)
IL (1) IL151683A0 (https=)
MX (1) MXPA02008967A (https=)
NO (1) NO20024381L (https=)
NZ (1) NZ521325A (https=)
RU (1) RU2002127733A (https=)
TW (1) TWI286932B (https=)
WO (1) WO2001068072A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69625678T3 (de) † 1995-12-18 2006-11-09 The University Of Utah Research Foundation, Salt Lake City Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
US6713268B2 (en) * 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
MXPA04000980A (es) * 2001-07-31 2004-04-20 Sucampo Ag Tratamiento de hipertension ocular y glaucoma.
WO2003082257A2 (en) * 2002-03-28 2003-10-09 Sucampo Ag Method for treating ocular hypertension and glaucoma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052735T3 (es) * 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
WO1990002553A1 (en) * 1988-09-06 1990-03-22 Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
TW224942B (https=) * 1990-04-04 1994-06-11 Adka Ueno Kk
AU687906B2 (en) * 1993-12-15 1998-03-05 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AU7680096A (en) * 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
AU1709699A (en) * 1997-12-22 1999-07-12 Alcon Laboratories, Inc. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
DE69909768T2 (de) * 1998-04-07 2004-06-17 Alcon Manufacturing Ltd., Fort Worth Xanthangummi enthaltende gelbildende ophthalmische zusammensetzungen

Also Published As

Publication number Publication date
MXPA02008967A (es) 2003-02-12
KR20080012407A (ko) 2008-02-11
WO2001068072A2 (en) 2001-09-20
NZ521325A (en) 2004-05-28
HUP0300391A2 (hu) 2003-06-28
RU2002127733A (ru) 2004-03-27
WO2001068072A3 (en) 2002-06-06
IL151683A0 (en) 2003-04-10
JP2003526660A (ja) 2003-09-09
BR0109192A (pt) 2003-05-27
CN100506232C (zh) 2009-07-01
TWI286932B (en) 2007-09-21
CZ20023092A3 (cs) 2003-05-14
AU4114301A (en) 2001-09-24
CA2402597C (en) 2011-04-26
AR029818A1 (es) 2003-07-16
EP1272194A2 (en) 2003-01-08
AU2001241143B2 (en) 2005-08-25
NO20024381D0 (no) 2002-09-13
CA2402597A1 (en) 2001-09-20
US20010056104A1 (en) 2001-12-27
HUP0300391A3 (en) 2008-05-28
CN1429112A (zh) 2003-07-09

Similar Documents

Publication Publication Date Title
NO20030610D0 (no) Nye sammensetninger av Minoksidil
ATE291433T1 (de) Extrakte von mutterkraut (tanacetum parthenium) gegen entzündliche erkrankungen
AU2001253038A1 (en) Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
DE60215919D1 (de) 4-fluoro-n-indan-2-yl benzamid und seine verwendung als arzneimittel
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
DE50115490D1 (de) Kosmetische zusammensetzung zur behandlung von alternder und/oder gestresster haut
NO20004550L (no) Enzyminhibitorer
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
BRPI0418245A (pt) nitróxi-derivados de prostaglandina
MXPA02007099A (es) Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina.
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
DK1228032T3 (da) Præparater, som indeholder hydroxyicosatetraensyrederivater, og fremgangsmåder til anvendelse ved behandling af öjentörhedslidelser
DK1235571T3 (da) Anvendelse af melatonin til behandling af androgenetisk eller diffus alopecia af feminin type
AR037556A1 (es) Composicion farmaceutica que comprende un abridor del canal de c1c-2
NO20052751L (no) Oftalmisk preparat for behandling av okulaer hypertensjon.
WO2001089536A3 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
PT1242410E (pt) Compostos novos
NO20024381L (no) Preparat for anvendelse ved behandling av okular hypertensjon og gluakom
AU2002332488A1 (en) R-bambuterol, its preparation and therapeutic uses
DK1463563T3 (da) Superoxiddismutas-mimetika til behandling af öjenlidelser og -sygdomme
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
BR0104082A (pt) Processo de tratamento conveniente para a deformação e/ou conformação, e isto de modo permanente, dos materiais queratìnicos e, particulamente, dos cabelos, composição cosmética redutora, e kit para tratamento
AU2001292698A1 (en) Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
DE602004025683D1 (de) Therapeutische zubereitung für autoimmune erkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application